Immunotherapy for malignant melanoma with a tumor cell vaccine.
Journal Article (Journal Article;Review)
Specific active immunotherapy for melanoma has been administered to several thousand patients since 1972, using an irradiated whole-cell preparation. A humoral response to vaccination can be demonstrated in a large percentage of patients. This response increases while immunizations are continued and decreases after cessation of therapy. The vaccinations are well tolerated; however, the therapeutic impact of this whole-cell vaccine awaits a randomized trial for definitive evaluation.
Full Text
Duke Authors
Cited Authors
- Slingluff, CL; Seigler, HF
Published Date
- January 1992
Published In
Volume / Issue
- 28 / 1
Start / End Page
- 104 - 107
PubMed ID
- 1642395
International Standard Serial Number (ISSN)
- 0148-7043
Digital Object Identifier (DOI)
- 10.1097/00000637-199201000-00026
Language
- eng
Conference Location
- United States